MIRM Q1 2023 Earnings — Mirum Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MIRMMirum Pharmaceuticals, Inc.

$5B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$32M+145.1% YoY

Gross Profit

$27M84.2% margin

Operating Income

-$27M-85.9% margin

Net Income

-$30M-95.4% margin

EPS (Diluted)

$-0.80

QoQ Revenue Growth

+13.2%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$34M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$334M

Total Liabilities

$192M

Stockholders' Equity

$141M

Cash & Equivalents

$49M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$32M	$13M	+145.1%
Gross Profit	$27M	$10M	+154.3%
Operating Income	-$27M	-$33M	+17.1%
Net Income	-$30M	-$37M	+17.7%

Revenue Segments

Product

$29M92%

License

$3M8%